immunotherapy

Moderna and Merck cancer vaccine cuts melanoma recurrence by 44% in late-stage trial

vor 6d

mRNA vaccine shows early promise against pancreatic cancer in phase 1 trial

vor 6d

Moderna and Merck vaccine cuts melanoma recurrence risk by 44% in phase 3 study

vor 6d

mRNA melanoma vaccine cuts recurrence risk by 44% in interim Phase 3 data

vor 6d